***Welcome to Stillman Translations preliminary onboarding assessment!***

*This assessment has 5 sections. Make sure to follow the instructions and complete all the information needed.*

*The goal of this request is to analyze your performance and your potential.*

*Breathe in and out, and do your best. Hope we can count on you soon!*

**SECTION 1. INSTRUCTIONS**

*Below you will find a special instruction for section 3:*

*\*Please make sure target text mirrors source format.*

*\*Normalize spaces.*

**SECTION 2. GLOSSARY**

*In this section, you are required to complete this task:*

*\*Extract four terms (cells 1 to 4) from the text in Section 3 that you consider are worth being in the glossary.*

|  |  |  |
| --- | --- | --- |
|  | **Source** | **Target** |
| 1 | Documented infection | Infección confirmada |
| 2 | Cohort | Grupo |
| 3 | In utero | Intrauterino |
| 4 | Postmenstrual age | Edad postmenstrual |

**SECTION 3. TRANSLATION**

*Please, add your sample translation below (between 300-500 words). Bear in mind this should be the best sample of your work!*

|  |  |
| --- | --- |
| **Source** | **Target** |
| SCHEMA  INTENSIVE TREATMENT OF HIV-INFECTED INFANTS TO ACHIEVE HIV REMISSION  DESIGN: Phase I/II proof of concept exploratory study  SAMPLE SIZE: Up to 472 infants, including 440 at high risk of *in utero* HIV infection and 32 with documented HIV infection, to yield a total of 54 HIV-infected infant subjects, will be enrolled. Mothers of enrolled infants will also be enrolled.  POPULATION: High-Risk, Cohort 1: Infants aged ≤ 48 hours of birth born to women with HIV infection who did not receive any antiretrovirals (ARVs) during pregnancy  AND  ART-Started, Cohort 2: Infants ≤ 10 days of age with documented in utero HIV infection who initiated antiretroviral therapy (ART) outside of the study within 48 hours of birth  STUDY DESIGN: Step 1: Cohort 1 infants will begin the study ART regimen within 48 hours of birth. If in utero HIV infection is confirmed, these infants will enter Step 2 two weeks after Step 1 entry; otherwise, they will remain in Step 1 for four weeks and then exit the study.  Step 2: Cohort 1 infants who are confirmed to have in utero HIV infection and all Cohort 2 infants will take the study ART regimen, which includes the addition of LPV/r when the infant reaches ≥ 14 days of age AND ≥ 42 weeks postmenstrual age.  STUDY DURATION:  Mothers will be enrolled at the time of the infant’s study entry for demographic data collection, targeted clinical history and HIV RNA testing. Mothers of infants identified as HIV-infected will have a single blood draw as soon as possible after the infant is identified as infected and will continue to be followed for interval clinical history as long as their infant remains in the study.  HIV-infected infants will be followed up to 5 years of age for ongoing evaluation for HIV remission, potential treatment toxicity, and clinical or laboratory progression.  Cohort 1 HIV-exposed infants who do not have in utero HIV infection and their mothers will exit the study at the Step 1 Week 4 visit.  OBJECTIVES:  Primary Objective:  To assess HIV remission among HIV-infected neonates who initiate ART within 48 hours of birth. For purposes of this protocol, remission is defined as having no confirmed plasma HIV RNA  LOD for 48 weeks following ART cessation. | ESQUEMA  TRATAMIENTO INTENSIVO PARA LA REMISIÓN DEL VIH EN BEBÉS INFECTADOS CON ESTE VIRUS  DISEÑO: Estudio exploratorio de prueba de concepto en Fase I/II  TAMAÑO DE LA MUESTRA: Se inscribirán un máximo de 472 bebés hasta alcanzar un total de 54 bebés infectados con el VIH, de los cuales 440 tienen un alto riesgo de infección por transmisión intrauterina y los restantes 32, infección del VIH confirmada. Las madres de los bebés inscriptos también formarán parte del estudio.  POBLACIÓN: Grupo 1, con alto riesgo: bebés de 48 horas de vida o menos, nacidos de madres con el VIH que no recibieron ningún tratamiento antirretroviral (ARV) durante el embarazo.  Y  Grupo 2, con tratamiento de ARV iniciado: bebés de 10 días de vida o menos, con infección por el VIH comprobada, transmitida de forma intrauterina, que hayan iniciado una terapia antirretroviral (TARV) fuera del estudio dentro de las primeras 48 horas de vida.  DISEÑO DEL ESTUDIO: Paso 1: los bebés del Grupo 1 comenzarán el régimen de TARV del estudio dentro de las primeras 48 horas de vida. Si se confirma la presencia del VIH intrauterino, los bebés infectados comenzarán el Paso 2 después de dos semanas del inicio del Paso 1. De lo contrario, permanecerán en el Paso 1 por cuatro semanas y saldrán del estudio.  Paso 2: los bebés del Grupo 1 con el VIH intrauterino confirmado y los del Grupo 2 seguirán el régimen de TARV del estudio, que incluye la incorporación de LPV/r cuando el bebé alcance o supere los 14 días de vida Y las 42 semanas de edad postmenstrual.  DURACIÓN DEL ESTUDIO  Se inscribirá a las madres cuando los bebés ingresen al estudio para la recolección de información demográfica, historia clínica dirigida y pruebas de ARN del VIH. Se tomarán muestras de sangre de las madres de los bebés identificados como portadores de VIH una única vez y lo antes posible después de que se identifique al bebé como infectado. Se hará un seguimiento a dichas madres por intervalos de historia clínica mientras sus bebés sean parte del estudio.  Los bebés con VIH estarán bajo seguimiento hasta que alcancen los 5 años de edad para evaluaciones continuas de remisión del VIH, posible toxicidad del tratamiento y evoluciones clínicas o de laboratorio.  Los bebés del Grupo 1 expuestos al VIH que no presenten VIH intrauterino y sus madres dejarán de participar del estudio en la visita de seguimiento de la Semana 4 del Paso 1.  OBJETIVOS:  Objetivo principal:  Evaluar la remisión del VIH en neonatos infectados que inician el tratamiento antirretroviral dentro de las 48 horas de vida. Para los propósitos de este protocolo, se define la remisión como la ausencia de plasma confirmado VIH ARN  LOD por 48 semanas después de terminar el TARV. |

**SECTION 4. QUESTIONS AND COMMENTS**

*We also need to check your capacity to spot potential issues beforehand.*

*In the table below, please list your questions and comments in relation with this test:*

*1. Challenging sections from the source text or sections you are unsure of should be copied or inserted into the* ***Source Text*** *column.*

*2. Write your translation in the* ***Target Text*** *column.*

*3. Doubts and comments should be written in English.*

|  |  |  |
| --- | --- | --- |
| **Source Text** | **Target Text** | **Question / Comment  (in English)** |
| no confirmed plasma HIV RNA  LOD for 48 weeks (…) | ausencia de plasma confirmado VIH ARN  LOD por 48 semanas (...) | If checked in the wrong field, LOD may vary its meaning. In both languages it’s used as an abbreviation for limit of detection. |
| Phase I/II proof of concept exploratory study | Estudio exploratorio de prueba de concepto en Fase I/II | As translators we should note that there is a fixed order when writing the name of the studies. |
| postmenstrual age | edad postmenstrual | We may think that the translation for this in Spanish is “después de la última menstruación” because it makes reference to that, or even “posmenstrual” as it fits TT’s spelling rules, but if we research we find that «postmenstrual»is a concept also used in Spanish. |
|  |  |  |
|  |  |  |

**SECTION 5. REFERENCES**

*In the table below, please list the reference material you have consulted to carry out this test.*

* *Please introduce the* ***Reference source*** *(including publisher and full title as appropriate) in the first column.*
* *Specify if your reference source is general or specific. If specific, clarify which term or section the reference covers.*

|  |  |
| --- | --- |
| **Reference Source** | **General / Specific (Term)** |
| *¿Qué es la Asistencia Domiciliaria? | PortalCLÍNIC. (2021). Retrieved 11 May 2021, from https://www.clinicbarcelona.org/asistencia/enfermedades/prematuridad/asistencia-domiciliaria#:~:text=Edad%20postmenstrual%20son%20las%20semanas,gestaci%C3%B3n%2C%20que%20son%2040%20semanas.* | *postmenstrual age* |
| *CAPITULO 4. (2021). Retrieved 11 May 2021, from http://servicios.infoleg.gob.ar/infolegInternet/anexos/90000-94999/91870/res649-2004-cap4.htm* | *postmenstrual age* |
|  |  |

Thanks!